Head-To-Head Analysis: IceCure Medical (NASDAQ:ICCM) vs. iCAD (NASDAQ:ICAD)

iCAD (NASDAQ:ICAD) and IceCure Medical (NASDAQ:ICCM) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares iCAD and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iCAD	-17.81%	-15.65%	-12.52%
IceCure Medical	-376.85%	-124.44%	-87.70%

Risk and Volatility

iCAD has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

Insider & Institutional Ownership

24.6% of iCAD shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 10.3% of iCAD shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares iCAD and IceCure Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iCAD	$17.32 million	3.01	-$4.85 million	($0.13)	-15.12
IceCure Medical	$3.23 million	20.96	-$14.65 million	($0.29)	-4.21

iCAD has higher revenue and earnings than IceCure Medical. iCAD is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for iCAD and IceCure Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iCAD	0	0	0	0	0.00
IceCure Medical	0	0	1	1	3.50

IceCure Medical has a consensus target price of $2.70, indicating a potential upside of 121.31%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than iCAD.

Summary

iCAD beats IceCure Medical on 9 of the 15 factors compared between the two stocks.

About iCAD

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.